BPC-157 mechanism, half-life, primary literature, what the corpus does and doesn't say. Research-grade reference for serious operators.
A 15-amino-acid synthetic peptide derived from a protective sequence in human gastric juice, sold for research use only and most often referenced in the soft-tissue and gut-repair preclinical literature.
BPC-157 stands for Body Protection Compound 157. It is a synthetic 15-amino-acid peptide. Its sequence is derived from a larger protective protein found in human gastric juice. It is not a hormone. It is not a steroid. It is not a GLP-1.
The compound was first isolated and characterized by Predrag Sikiric and his collaborators at the University of Zagreb beginning in the early 1990s. Sikiric's group has published the bulk of the foundational work on this molecule for nearly thirty years. If you read one author on BPC-157, you read Sikiric.
In commercial markets it is sold as an RUO — research use only — peptide. It is not approved as a drug in the United States. It is not approved as a drug in the European Union. The FDA flagged it in 2022 as ineligible for compounding under section 503A. None of that has stopped the founder-biohacker community from buying it. It is the math operators are choosing to do under their own labs, with their own physician relationships, eyes open.
This page is mechanism, half-life, and where the literature lives — not bro-science.
BPC-157 does not have a single named receptor it binds the way a GLP-1 agonist binds GLP-1R. The mechanism in the literature is upstream and diffuse, which is part of why the marketing has run so far ahead of the science.
The current preclinical picture, mostly from Sikiric's lab and a handful of independent groups, points to several converging effects:
Growth factor receptor upregulation. Animal models show BPC-157 upregulating receptors for VEGF — vascular endothelial growth factor, the primary signal for angiogenesis, the formation of new blood vessels — at sites of injury. More VEGF receptors at an injury site means more capillary ingrowth, which is one rate-limiting step in soft-tissue healing.
Nitric oxide system modulation. The peptide appears to interact with the NO pathway, with downstream effects on vascular tone and platelet behavior in rodent models. This is the cleanest story in the corpus.
Gut–brain axis effects. Animal work documents modulation of dopaminergic and serotonergic signaling, which is why a soft-tissue compound shows up in CNS, mood, and behavioral studies in the rodent literature. People new to BPC-157 are often surprised the corpus spans tendons, gut wall, and brain. That is the corpus.
The honest summary: the literature describes a compound that appears to accelerate the body's own repair signaling at multiple points in the cascade, in animals, at doses that have not been replicated in human RCTs.
The literature reports BPC-157 plasma half-life under one hour for injected forms in animal models. Some pharmacokinetic work places it closer to thirty minutes. The molecule is small, it is not pegylated, and it is not albumin-bound. Short clearance is consistent with that chemistry.
Subcutaneous injection is the dominant route in published work. Intraperitoneal and intramuscular routes appear in animal studies. Oral administration shows up specifically in gastrointestinal studies, where the local effect on the gut wall does not require systemic bioavailability. Topical and intranasal preparations exist in community circles, but the published support for those routes is thin.
Frequency of administration in published animal work clusters around once or twice daily. Human pharmacokinetic data is essentially absent.
This is the most important section on this page. Read it twice.
Tier 1 — Randomized controlled trials in humans. None. There is no published Phase 2 or Phase 3 RCT for BPC-157 in humans for any indication.
Tier 2 — Open-label or single-arm human work. Effectively none in peer-reviewed indexed journals. A small number of case reports and clinic-level write-ups exist. They do not constitute a Tier 2 corpus.
Tier 3 — Animal and mechanistic. This is the entire BPC-157 evidence base. Sikiric et al. across two decades — gut ulcer models, tendon transection models, ligament transection models, vascular occlusion models, dopaminergic models. Chang et al., 2011 in the Journal of Applied Physiology on tendon outgrowth and cell migration in rat tendon explants. Multiple narrative reviews summarizing the rodent corpus published 2020 through 2024. Search "Sikiric BPC-157" and "BPC-157 review" on PubMed and you have most of it.
Tier 4 — Operator n=1. Substantial. Tendon and joint reports. Gut symptom reports, particularly NSAID-related. The community signal is real. It is also Tier 4.
The literature is mostly preclinical. The marketing is not. That gap is the thing this page exists to make legible.
Tendon and joint pain are the most commonly reported subjective change, often inside the two-to-four-week window. Achilles, rotator cuff, elbow, knee — the same complaints that send the cohort to physical therapists in the first place.
Gut symptom reports are frequent. NSAID-induced gastric irritation is the most-cited use case in community reports. Operators describe pairing oral and injected use for combined local and systemic exposure.
PIP — post-injection pain — is generally rated low. The peptide is small, it dissolves cleanly in bacteriostatic water, and operators report subcutaneous injections as well-tolerated relative to oilier compounds.
BPC-157 is most often stacked with TB-500 in what forum users call the Wolverine stack. Some operators add GHK-Cu for skin and connective tissue. Stacks vary. Reports vary. The signal is not uniform, and we do not pretend it is.
This is community framing summarized neutrally. It is not endorsement.
A short list, in order of importance.
Long-term human safety. Unstudied. The animal corpus runs out to weeks and months in rodent models. Humans live longer. What chronic exposure looks like in a 40-year-old founder running this compound for years is not in the literature. It is a real open question.
Oral bioavailability. Contested. Sikiric's gut-focused work uses oral routes for local effect on the gut wall. Whether oral BPC-157 produces clinically meaningful systemic exposure in humans is not settled.
Tumor and angiogenesis interaction. A pro-angiogenic compound in someone with an undiagnosed solid tumor is a theoretical concern that has not been ruled in or out by published work.
Dose-response. Animal dosing scales to human equivalents in ways the literature does not cleanly support. Community dosing varies by an order of magnitude across reports. The literature does not arbitrate.
Active-fragment versus full-sequence behavior. Some vendor product is shipped as the stable acetate salt; some is shipped as alternative formulations. The literature is cleanest on the parent sequence.
BPC-157 is the recovery anchor for most operator stacks in this cohort. The full peptide map sits in Issue 1: The 2026 Peptide Stack Map — fourteen compounds, mechanism through literature, one page each. Issue 5 goes deeper on the soft-tissue stack and how operators sequence BPC-157 with TB-500 and GHK-Cu.
If recovery and injury are the reason you are reading this page, the lead magnet to pull is the Wolverine Recovery Stack PDF — BPC-157, TB-500, GHK-Cu, mechanism through literature, in one document, free.
Adjacent compounds on this site: TB-500 and GHK-Cu.
Three compounds. One reference document. Mechanism, half-life, primary literature, and where the corpus thins.
Subscribe to The Compound at https://www.thecompoundbrief.com/subscribe and the PDF lands in your inbox.
For research use only. Not medical advice. Nothing on this page is a recommendation to administer, prescribe, or self-administer any compound.
Disclosure: The operator who publishes The Compound also owns heroxbio.com, an RUO peptide vendor. Full disclosure on the About page.
BPC-157, TB-500, and the recovery lane — what the literature actually shows.
Download the PDF →